Light Mode
$7.17 ↑ +0.00 (+0.00%) Trading Up from the previous close of $7.17, $0.30 below the day’s high of $7.47
-6.54 (-47.70%) / 6M
Momentum, market sentiment, and recent alerts
AVTX reads not so good: price sits below both the 20- and 200-day averages, the 12-month move is -57.0%.
No alerts for AVTX in the last day.
Earnings, valuation, and balance sheet
Company profile and competitor comparison
Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. It also focuses on reducing LIGHT levels which can moderate immune dysregulation in many acute and chronic inflammatory disorders. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Wayne, PA.
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.